Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women whith Early Stage Breast Cancer (SWOG 1200)...

A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial...

A randomized phase III study pf adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer...

NSABP B-47 (NRG Oncology) Phase III RCT Comparing Adjuvant Chemotherapy AC-Weekly Paclitaxel (WP) or TC x 6 with or without Trastuzumab for 1 Year in High-risk, Invasive Breast Cancer, Negative for HER2 by ISH and with IHC 1+ or 2+ (HER2-Low IBC)...

Increasing the dose intensity of adjuvant chemotherapy: an EBCTCG meta-analysis...

Phase Ib/II Study Evaluating Safety and Efficacy of Pembrolizumab and Trastuzumab in Patients with Trastuzumab-Resistant HER2-positive Advanced Breast Cancer: Results from the PANACEA Study (IBCSG 45-13/BIG 4-13/KEYNOTE-014)...

Az Amgen Kft. onkológiai üzletágának munkatársai tisztelettel meghívják Önt az Amgenius Akadémia rendezvényére. Időpont: 2018. március 23-24. (péntek-szombat) Helyszín: HOTEL FÜRED, Balatonfüred...

First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial....

Exposure-response and PD-L1 expression analysis of second-line avelumab in patients with advanced NSCLC: Data from the JAVELIN Solid Tumor trial....

Analysis of serum vitamin D levels and prognosis in stage III colon carcinoma patients treated with adjuvant FOLFOX+/- cetuximab chemotherapy: NCCTG N0147 (Alliance)....

Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study....

Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity....

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study....

Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity....

IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC....

Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study. (ICML-Lugano) How we can improve first line treatment for follicular lymphoma and how to measure improvement?...

Studies about new agents that look promising SABCS + ESMO (Breast Cancer topics) (PERTAIN Pertuzumab in Combination With Trastuzumab)...

First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results....

Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476)....